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Abstract
Background: The clinical pathway to detect and diagnose prostate cancer has been revolutionised by the use of
multiparametric MRI (mpMRI pre-biopsy). mpMRI however remains a resource-intensive test and is highly operator
dependent with variable effectiveness with regard to its negative predictive value. Here we tested the use of the
phi assay in standard clinical practice to pre-select men at the highest risk of harbouring significant cancer and
hence refine the use of mpMRI and biopsies.
Methods: A prospective five-centre study recruited men being investigated through an mpMRI-based prostate
cancer diagnostic pathway. Test statistics for PSA, PSA density (PSAd) and phi were assessed for detecting
significant cancers using 2 definitions: ≥ Grade Group (GG2) and ≥ Cambridge Prognostic Groups (CPG) 3. Cost
modelling and decision curve analysis (DCA) was simultaneously performed.
Results: A total of 545 men were recruited and studied with a median age, PSA and phi of 66 years, 8.0 ng/ml and 44
respectively. Overall, ≥GG2 and ≥ CPG3 cancer detection rates were 64% (349/545), 47% (256/545) and 32% (174/545)
respectively. There was no difference across centres for patient demographics or cancer detection rates. The overall area
under the curve (AUC) for predicting ≥GG2 cancers was 0.70 for PSA and 0.82 for phi. AUCs for ≥ CPG3 cancers were
0.81 and 0.87 for PSA and phi respectively. AUC values for phi did not differ between centres suggesting reliability of the
test in different diagnostic settings. Pre-referral phi cut-offs between 20 and 30 had NPVs of 0.85–0.90 for ≥GG2 cancers
and 0.94–1.0 for ≥ CPG3 cancers. A strategy of mpMRI in all and biopsy only positive lesions reduced unnecessary
biopsies by 35% but missed 9% of ≥GG2 and 5% of ≥ CPG3 cancers. Using PH≥ 30 to rule out referrals missed 8% and
5% of ≥GG2 and ≥ CPG3 cancers (and reduced unnecessary biopsies by 40%). This was achieved however with 25%
fewer mpMRI. Pathways incorporating PSAd missed fewer cancers but necessitated more unnecessary biopsies. The phi
strategy had the lowest mean costs with DCA demonstrating net clinical benefit over a range of thresholds.
Conclusion: phi as a triaging test may be an effective way to reduce mpMRI and biopsies without compromising
detection of significant prostate cancers.
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Background
Prostate cancer is the most common male cancer in the
western world and its incidence is rising. One of the big-
gest conundrums facing health care systems is how best
to detect and diagnose potentially life-limiting disease
while not simultaneously over-investigating and finding
indolent tumours. The use of multiparametric magnetic
resonance imaging (mpMRI) pre-biopsy is now firmly
embedded in the prostate cancer diagnostic pathway as a
method to try and address this [1–5]. This enables tar-
geting of positive lesions and in the case of negative im-
aging, avoiding biopsy all together in a proportion of
referrals [5]. There remains, however, significant limita-
tion with mpMRI particularly around costs, access, qual-
ity control, sustainability and meeting the needs of a
growing population of ageing men, only some of whom
will harbour lethal disease [6–8]. mpMRI also has sig-
nificant operator-dependent variability and its negative
predictive value is known to vary from study to study
depending on scanner type, sequences selected and radi-
ologist experience [9, 10]. As a result, the European As-
sociation of Urology (EAU), amongst other bodies, has
called for research into pre-MRI triage tests to refine
and improve the use of mpMRI [11]. A few studies have
now tested combinations of biomarkers and imaging in
controlled trials [12–15]. On-line risk calculators are
also available and have recently been updated to include
mpMRI data in their predictive algorithms [16]. To date,
however, few have considered how biomarker-imaging
combinations might work to refine the use of tests and
hence cost-effectiveness.
The prostate health index (phi) is one of the most
robustly studied prostate cancer biomarkers in the litera-
ture and also one of the lowest cost tests available [17–
19]. It has consistently shown better predictive value
compared to PSA in detecting prostate cancer in numer-
ous studies in many countries and has been combined
with on-line risk calculators [20]. Previous work in our
group was the first to combine phi with mpMRI demon-
strating its utility in triaging who needs re-biopsy from
an initial negative investigation [21]. Here we have ex-
tended that work to test the use of the phi in a multicen-
tre first referral population. Our principle question was
if the phi test could reduce mpMRI/biopsy use without
compromising detection of prognostically important
cancers. Importantly, if this could be done in a routine
diagnostic service real-world context without controlling
for imaging and biopsy methodology.
Methods
Patients and data acquisition
Five UK centres took part with each recruiting consecutive
men referred from primary care for elevated prostate-
specific antigen (PSA) (January 2018 to June 2019.) mpMRI
method and reading and biopsies were carried out accord-
ing to local protocols in order to ground the study in real-
world practices. The only stipulation was image-guided tar-
gets + systematic biopsies (cognitive or image fusion). Men
were excluded if they had (i) a previous biopsy, (ii) pelvic
metalwork interfering with mpMRI quality or no mpMRI
and (iii) if no biopsy was done after mpMRI. PSA and phi
assay was taken before biopsy and PSA density (PSAd) cal-
culated using mpMRI-defined prostate volumes. Only men
with intact information on key data points, PSA (ng/mL),
phi, mpMRI, prostate volume, biopsy performed, histo-
logical Grade Group and clinical tumour stage (T-stage)
were included in the final analysis. Men with missing data
from the original 554 were not included in the analysis leav-
ing a final study cohort of 545 (Additional File Fig. S0).
Additional File Table S1 details the imaging and biopsy
strategy in each unit. Men with mpMRI-negative lesions
had systematic sectoral biopsies only. The study was con-
ducted under ethics REC 03/018.
phi assay
phi assays were handled according to the manufacturer’s
recommendations (Beckman Coulter). Blood was taken
prior to biopsies and before prostate manipulation. Sam-
ples were centrifuged and frozen at – 80 °C within 3 h
before dispatch to a central laboratory and performed on
a Beckman Coulter Access Autoanalyser. Quality Assur-
ance samples were analysed before and after each batch
to ensure the validity of the results. All QC results were
within Beckman Coulter’s target ranges. phi results were
not viewed or analysed till after all men had been re-
cruited. There were no adverse events from the extra
sampling.
mpMRI
mpMRI on 1.5 T or 3 T systems with multi-channel
surface phased array coils were performed including
standard anatomical and functional imaging (diffusion-
weighted and contrast enhanced). Image acquisition and
processing was performed in accordance with local
standard clinical protocols. In all centres, sequences
were evaluated and scored using a Likert scale of cancer
probability, based on the Prostate Imaging Reporting
and Data ver. 2 (PI-RADS version 2). Prostate volumes
were calculated from mpMRI images. Likert 1–2 (M1-
M2) lesions were considered mpMRI negative for this
study and positive lesions graded as M3-M5. Lesion call-
ing was left to local expertise without specification of
reader experience.
Statistical analysis and decision modelling
The primary end-points were two definitions of prognostic-
ally important cancers (i.e. cancers that may shorten life-
expectancy if not found). For this, we used International
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or more on biopsy (≥GG2) and prognostic group 3 or
more using the composite Cambridge Prognostic Group
(CPG) prognostic score (≥CPG3) we have previously re-
ported and validated [22]. CPG is a five-tiered multi-factor
(PSA, Grade and Stage) prognostic model for non-
metastatic prostate cancer shown to have superior discrim-
ination in predicting prostate cancer deaths compared to
any other tiered stratification systems [23]. Disease ≥CPG3
is similar to unfavourable intermediate risk and high-risk
disease in the AUA, NICE and EAU systems [24]. Areas
under the receiver-operating curve (AUC) and diagnostic
test statistics for different strategies were compared to PSA
alone: phi and PSAd. We adopted a decision modelling ap-
proach to bring together information about sensitivity, spe-
cificity and costs. A range of potential clinical pathways
were modelled and compared Strategy 1: mpMRI and bi-
opsy all, Strategy 2: mpMRI all and biopsy if positive, Strat-
egy 3: mpMRI all and biopsy if PSAd ≥ 0.15, Strategy 4:
mpMRI all and biopsy if PSAd ≥ 0.1, Strategy 5: phi all and
mpMRI and biopsy if phi ≥ 25, Strategy 6: phi all and
mpMRI and biopsy if phi ≥ 30. The proportions of men
with positive test results in the study cohort were used to
calculate cancers detected or missed under each pathway.
Additional Figure S2 shows the pathway and cohort per-
centages corresponding to Strategy 6. Costs for assays,
scans and biopsies are given in Supplement Table S2; one-
way sensitivity analyses were used to explore the impact of
assumptions regarding the cost and risk of sepsis following
biopsy. Key outcomes relating to correctly identified can-
cers (true positives), incorrectly identified cancers (false
positives), missed cancers (false negatives), numbers of MRI
scans, numbers of biopsies and total costs were then calcu-
lated for a hypothetical cohort of 1000 referred individuals.
Decision curve analysis
Decision curve analysis (DCA) was done to estimate the
clinical net benefit outcome, which accounts for the per-
ceived value weighting between the harms of biopsy in
those without cancer and the harms of not identifying
those with cancer [25]. The value weighting represents the
decision-makers’ beliefs about the benefit to harm ratio
between cancer detection and unnecessary biopsy. It can
be thought of as the risk of cancer at which there is equi-
poise about whether to proceed to biopsy (risk threshold,
RT) and takes values between 0 and 1. A low risk thresh-
old implies that the perceived harm of biopsy is low com-
pared to the benefits of identifying cancer; conversely, a
high-risk threshold occurs when biopsy harm is high com-
pared to the benefits of identifying cancers. The clinical
net benefit is then calculated (at a given value of RT) as
the number of cancers detected minus the number of un-
necessary biopsies weighted by RT. Since the perceived
point of biopsy equipoise is uncertain, results are
presented over a range of RT values. The preferred detec-
tion strategy is then indicated by the one with the highest
net benefit, at a given RT. The cost per net cancer de-
tected under each strategy is also presented.
Results
Cohort description and between centre comparison
The final study population included 545 men with a me-
dian age of 66 years, PSA of 8 ng/ml and phi of 44
(Table 1). Overall mpMRI results were reported as posi-
tive (M3-M5) in 420/545 (77%) with M4-M5 lesions
found in 316/545 (58%) (Table 1). The median number
of cores taken was 16 for systematic biopsies and 2 for
targets (if positive on an mpMRI). Overall, prostate can-
cer was detected in 349/545 men (64%) and ≥GG2 can-
cers in 256/545 (47%). Using the composite CPG score,
disease ≥CPG3 was found in 174/545 men (32%). Add-
itional File Table S1 details the MRI positivity and
method of biopsy acquisition for each centre. There
were no significant differences between centres in any of
these parameters despite no pre-specified standardisa-
tion for diagnostic method and reporting [26, 27].
Performance of PSA, PSAd and phi in predicting prostate
cancer at biopsy
For detection of significant cancers defined as ≥GG2,
the AUCs were 0.70, 0.79 and 0.82 for PSA, PSAd and
phi respectively (Fig. 1a and Table 2). Both PSAd and
phi performed significantly better than PSA alone in pre-
dicting ≥GG2 disease (p < 0.001) (Table 2). The predict-
ive value of phi for ≥GG2 was also similar across all 5
centres (p = 0.67). The combination of PSA, PSAd with
imaging increased the AUC to 0.76 and 0.81 respectively
(Table 2). Using ≥CPG3 as an endpoint, the AUCs were
0.81, 0.84 and 0.87 for PSA, PSAd and phi respectively
(Additional File Figure S1A and Table 2). However, only
phi was significantly better than PSA in predicting ≥
CPG3 disease (p < 0.001) (Table 2). Amongst mpMRI-
negative men (n = 125), the AUCs for detection of ≥
GG2 cancers were 0.64, 0.76 and 0.78 respectively with
both PSAd and phi performing better than PSA. Neither
PSAd nor phi however performed better than PSA in
predicting the presence of ≥CPG3 disease (Fig. 1b,
Table 2 and Additional File Figure S1B).
phi thresholds in selecting men for referral to mpMRI and
biopsy
We next tested different threshold of the phi to test its
ability to triage men for initial mpMRI and biopsy. Using
detection of ≥GG2 as an endpoint, phi cut-offs ≥ 20 and
≥ 30 to refer for mpMRI and biopsy had an NPV of 0.85
and 0.90 respectively and missed 1.1 and 7.7% of tu-
mours (Table 3). With ≥CPG3 as a detection target, phi
performance showed even better results with NPVs of
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0.94 and 1.0 respectively and with 0% and 4.5% of can-
cers missed. Of note, using a phi ≥ 35 threshold (which
we reported for re-biopsy men) produced rather poor
sensitivity [21] (Table 3). This suggests that useful phi
thresholds may be different depending on the detection
context. As a comparator, we also analysed the perform-
ance of PSAd (noting that this is not usually available
before mpMRI). PSAd thresholds of ≥ 0.1, ≥ 0.15 and
≥ 0.2 missed between 7 and 31% of ≥GG2 cancers and
3–20% of ≥CPG3 tumours (Table 3).
Impact of using phi as a triaging test into an image-
guided diagnostic pathway
We next compared different pathways to model referrals
with and without use of phi. Table 4 summarises the key
modelling results for each strategy, based on a hypothet-
ical cohort of 1000 men referred for suspected prostate
cancer. The base case model was an mpMRI and biopsy
for all which detected every cancer but required more
than half of men (53%) to undergo unnecessary biopsies
(i.e. benign histology or ≤GG2) (Table 4). Each alterna-
tive option resulted in an overall reduction in biopsy
procedures, with the most impactful being a strategy to
only biopsy men with positive mpMRI (M3–5) or to
only biopsy men with a phi of ≥ 30 (23% and 25% reduc-
tion respectively). phi ≥ 30 also achieved this with a con-
comitant 25% reduction in mpMRI use by virtue of
being an upfront triage test. We next assessed the im-
pact on rates of detection of significant cancers. Using
detection of ≥GG2 as an endpoint, a strategy of mpMRI
and biopsy only positive cases reduced unnecessary pro-
cedures by 35% but did miss 9% of tumours. In contrast,
the phi ≥ 30 option to triage in referrals reduced un-
necessary biopsies by 40% and missed 8% of ≥GG2 can-
cers. The phi ≥ 25 option missed even fewer ≥GG2
cancers (4%), but only reduced unnecessary biopsies by
25%. Using detection of ≥CPG3 as an endpoint, both
strategies of mpMRI and biopsy-positive lesions and
using phi ≥ 30 led to similarly low missed cancer detec-
tion rates (5%); however, the phi ≥ 30 route required
fewer unnecessary biopsies (31% vs 35%). Other path-
ways using PSAd (≥ 0.10 and 0.15) required many more
overall biopsies (reductions of only 6–12%) and by defin-
ition all needed mpMRI (Table 4). These strategies did
though miss many fewer ≥GG2 tumours (1–2%) and no
≥CPG3 disease (Table 4).
Cost modelling and decision curve analysis
Table 4 includes the mean cost per investigated patient
for each of the modelled diagnostic strategies. Compared
to a cost of £965/person (mpMRI + biopsy) for all re-
ferred men, using a phi ≥ 30 threshold to restrict investi-
gations reduced costs by 20% (£774/person). In contrast,
a strategy of mpMRI + biopsy for only scan-positive
cases was marginally costlier (£796/person). Strategies
that involved using PSAd were also more expensive
mainly due to the increased use of both mpMRI and bi-
opsy (mean cost £879 and £921 for PSAd ≥ 0.15 and 0.10
respectively). Sensitivity analyses using higher rate or
cost for sepsis following biopsy showed little impact on
these comparisons (results not shown). Figure 2 shows
the results of the decision curve analysis (incorporating
the perceived harms of biopsying those without cancer)
in terms of net clinical benefit resulting from different
strategies based on ≥GG2 tumour detection. At very
low values of the risk threshold, biopsy all is the optimal
strategy because these values represent a belief that there
is little to no harm associated with an unnecessary bi-
opsy. For risk thresholds 0.2–0.5 (the estimated range of
uncertainty in clinical practice), the net benefit is highest
under the phi ≥ 30 pathway. Since this is also the cheap-
est option (Table 4), this appears to be the optimal test-
ing strategy representing a cost/cancer detected of
between £2120 and £5860 (Additional File Table S3), de-
pending on the risk threshold. However, for risk thresh-
olds < 0.2 (i.e. where there is uncertainty to biopsy at
cancer risk < 20%), the clinical net benefit is maximised
by using more costly strategies. The optimal decision at
these lower-risk thresholds therefore depends on the
willingness to pay/cancer detected (Additional File Table
S3). Hence for risk thresholds < 0.2, the cost for the
phi ≥ 30 strategy is around £2000/cancer detected but
more cancers (net) could be found using other strategies,
at the cost of £4000 to £8000/additional cancer depend-
ing on the pathway.
Discussion
In this paper, we report that use of the phi as a triage
test could reduce both imaging and biopsies by a quarter
while maintaining diagnostic efficiency using two defini-
tions of clinically significant prostate cancers. We further
Table 1 Descriptive characteristics of the primary study cohort.
MRI positive data is shown as the PI-RADS score of ≥ 3 or ≥ 4.
Detection rates for cancer are shown for any cancer, and using
definitions of ≥ Grade Group 2 (GG2 or ≥ Cambridge Prognostic
Group 3 [CPG3]. Excludes 9 men with missing data not included
in the analysis
Cohort descriptors N = 545
Age (median) (inter-quartile range) 66 (60,70) years
PSA (median) (inter-quartile range) 8 (6,13) ng/ml
PHI (median) (inter-quartile range) 44 (30,69)
MRI (3–5) 77%
MRI (4–5) 58%
Any cancer detection 64%
≥GG2 cancer detection 47%
≥ CPG3 cancer detection 32%
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demonstrate that introducing the phi is likely to be both
the cheapest per referred patient and cheapest per net
tumour detected.
The phi is one of many biomarkers reported in the last
10 years that have shown stronger predictive accuracy
compared to PSA in detecting prostate cancer [20, 21].
Early studies compared these biomarkers head to head
against mpMRI, but inevitably mpMRI proved superior
as not only does it improve detection but also helps
guide biopsies [28–30]. Subsequent studies have sought
to combine biomarkers with mpMRI with all showing
consistently better results than biomarkers alone but
often in a retrospective setting. One notable prospective
study combined the Stockholm3 test with mpMRI and
showed the combination was more accurate than each
individual test in detecting prostate cancer [14]. These
A
B
Fig. 1 ROC curve illustrating performance of phi, PSA, PSAD and mpMRI in predicting cancer diagnosis of ≥ Grade Group 2 (GG2) in the a whole
cohort and b mpMRI-negative men (PI-RADS≤ 3)
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studies, however, have generally not considered the in-
cremental cost implications and therefore whether tests
can be used sequentially [11, 31].
Recent work improving risk calculator performance
using biomarkers and/or mpMRI have tended to use
prostate biopsy as the end point [32, 33]. One exception
is the work by Mannaerts et al. who retrospectively ap-
plied the Rotterdam Prostate Cancer risk calculator in
200 men and proposed that the calculator could have re-
duced mpMRI by 37% [34]. An updated calculator in-
corporating mpMRI was developed but in a recent
prospective study did not improve prediction in biopsy
naïve men but did do so for a re-biopsy population [35].
This suggests that simply modifying existing calculators
with new parameters may need careful re-evaluation to
test applicability. Particularly, if once “free” calculators
start to incorporate costly biomarkers and imaging data
points. In this regard, an advantage of our current study
is its prospective application in a real-world setting and
simultaneous cost analysis.
Our cost modelling suggests that a phi-based triage path-
way may be less costly than other existing strategies. This is
particularly relevant as mpMRI is now a mandatory pre-
requisite step before prostate biopsy and hence an essential
diagnostic cost [5]. Bi-parametric instead of multiparametric
MRI may be cheaper but their comparative effectiveness re-
mains debated [36, 37]. The cost of biomarkers also remains
controversial with different studies showing varying results
[38–40]. It is however notable that the phi test as costed by
the manufacturer appears to be the most affordable
amongst available biomarkers [19]. In this study, we found
that it was both the cheapest per referred patient and the
cheapest per tumour detected. Although other strategies
(mpMRI and biopsy all or using PSAd) detected more pros-
tate cancers, it came at a significantly higher cost as a result
of having to undertake many more procedures.
This paper has many strengths. Key is the multicentre
design in five different image-guided standard of care
prostate diagnostic pathways. These are also limitations as
there was no central quality assurance of biopsy method,
histology and imaging. We also cannot account for deci-
sions to not do biopsy if an mpMRI was negative as prac-
tice differed amongst sites and was evolving. Despite this,
we were reassured to see that cancer detection rates and
phi test performance were similar across centres. Detec-
tion rates were also comparable if not higher than many
other published series which have used much more strin-
gent trial parameters [41–43]. Our cost modelling was
Table 2 Descriptive characteristics of the primary study cohort.
MRI positive data is shown as the PI-RADS score of ≥ 3 or ≥ 4.
Detection rates for cancer are shown for any cancer, and using
definitions of ≥ Grade Group 2 (GG2 or ≥ Cambridge Prognostic
Group 3 [CPG3]
≥GG2 cancer
detection
p value
(vs. PSA)
≥ CPG3 cancer
detection
p value
(vs.PSA)
Whole cohort
PSA 0.70 (0.66–0.74) – 0.81 (0.78–0.85) –
PSAd 0.79 (0.75–0.83) < 0.001 0.84 (0.80–0.87) 0.12
phi 0.82 (0.78–0.85) < 0.001 0.87 (0.84–0.90) < 0.001
MRI 0.63 (0.59–0.66) < 0.001* 0.63 (0.60–0.66) < 0.001*
MRI + PSA 0.76 (0.72–0.80) < 0.001 0.85 (0.81–0.88) 0.03
MRI + PSAd 0.81 (0.77–0.84) < 0.001 0.85 (0.81–0.88) 0.08
MRI + phi 0.81 (0.78–0.85) < 0.001 0.86 (0.83–0.90) 0.02
MRI negative
PSA 0.64 (0.52–0.76) – 0.86 (0.76–0.97) –
PSAd 0.76 (0.64–0.87) 0.01 0.95 (0.91–0.99) 0.08
phi 0.78 (0.66–0.90) 0.01 0.89 (0.74–1.00) 0.76
Table 3 Diagnostic test statistics of the study cohort showing the accuracy and missed cancer rates for each phi threshold as a
triage test pre-MRI and biopsy. PSAd thresholds are shown as a comparator though this metric is not usually available before an
mpMRI. Detection rates for cancer are shown using definitions of ≥ Grade Group 2 (GG2) or ≥ Cambridge Prognostic Group 3
[CPG3]. (*percentage out of 258 cancers detected, ** percentage out of 176 cancers detected)
≥GG2 cancer detection ≥ CPG3 cancer detection
Threshold Sensitivity Specificity NPV % cancers
missed*
Sensitivity Specificity NPV % cancers
missed**
phi 20 0.99 0.10 0.90 1.1 1.00 0.08 1.00 0
25 0.96 0.25 0.87 4.2 0.99 0.22 0.99 0.05
30 0.92 0.40 0.85 7.7 0.95 0.35 0.94 1.0
35 0.87 0.55 0.83 12.8 0.93 0.49 0.93 7.3
PSAd 0.10 0.93 0.31 0.82 7.3 0.97 0.28 0.95 2.8
0.15 0.81 0.57 0.77 18.6 0.90 0.53 0.92 9.6
0.20 0.69 0.77 0.73 31.3 0.80 0.72 0.88 20.0
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based on UK tariffs and extrapolation to other settings is
dependent on individual tariffs in other countries. We
note however that mpMRI-phi cost differentials are much
greater in Europe and the USA. We did not compare per-
formance of the phi with other biomarkers as these were
not available to us. The Stockholm3 study showed very
comparable results with a 10% risk threshold reducing
mpMRI and biopsies by 40% and missing 8% of cancers
[14]. A cost analysis was not published.
Conclusion
We present here a first study reporting use of the phi
test as a way of refining and reducing both mpMRI and
biopsies in investigating suspected prostate cancer. Se-
quential use of the phi and then mpMRI ± biopsy may
therefore be an efficient and effective way of identifying
those men who will benefit most from investigation
hence reducing cost and resource use in a rapidly grow-
ing disease demographic.
Table 4 Modelling results for a hypothetical cohort of 1000 patients referred for elevated PSA using different strategies for cancer
detection. In brackets are projected reductions compared to the base model (* compared to MRI + biopsy all)
Pathway
MRI + biopsy all MRI all + biopsy
if M3–5
MRI all + biopsy
if M3–5 or PSAd
≥ 0.15
MRI all + biopsy
if M3–5 or PSAd
≥ 0.10
MRI + biopsy
only if phi≥ 25
MRI + biopsy
only if phi≥ 30
No. of MRI scans (% lower*) 1000 1000 (0%) 1000 (0%) 1000 (0%) 850 (−15%) 750 (−25%)
No. of biopsies needed (% lower*) 1000 772 (−23%) 884 (−12%) 941 (−6%) 850 (−15%) 750 (−25%)
Detection of ≥ GG2 cancers
Cancers identified (% lower*) 100% 91% (−9%) 98% (−2%) 99% (−1%) 96% (−4%) 92% (−8%)
Unnecessary biopsies (% lower*) 527 343 (−35%) 420 (−20%) 471 (−11%) 396 (−25%) 314 (−40%)
Detection of ≥ CPG3 cancers
Cancers identified (% lower*) 100% 95% (−5%) 100% (0%) 100% (0%) 99% (−1%) 95% (−5%)
Unnecessary biopsies (% lower*) 677 466 (−31%) 562 (−17%) 618 (−9%) 529 (−21%) 442 (−35%)
Cost analysis
Cost/pt. (% lower*) £965 £796 (−18%) £879 (−9%) £921 (−5%) £869 (−10%) £774 (−20%)
Fig. 2 Decision curve analysis comparing the number of net benefits for detection of significant cancers for a range of risk threshold values and
using different approaches (MRI-PSAd using a PSAd threshold of ≥ 0.15). MRI - magnetic resonance imaging, PSAd - PSA density, phi - Prostate
Health Index
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Additional file 1: Figure S0. Flow chart of recruitment and tests and
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Prognostic Group 3 [CPG3] in A. Whole cohort and B. mpMRI negative
men (PI-RADS≤3). Figure S2. Decision tree pathway and percentages
based on phi>30 pathway. Table S1. Profile of imaging and diagnostic
method at each of the centres in the study. Table S2. Model parameters:
base case values. Costs ascribed for each event. Table S3. Costs per net
cancer detected, by risk threshold. It is assumed that at risk thresholds
>0.5 (risk of cancer >50%), there would be clinical consensus that the
perceived harms of biopsy are outweighed by the benefits of detecting
and treating any cancer).
Acknowledgements
We are grateful for the assistance of Dr. Tristan Barret, Dr. Anne Warren, Sr
Lorraine Starling (Cambridge), Dr. Sid Liyanage, Dr. Konrad Wolfe (Southend),
Sr Connie Shiridzinomwa, Sr Carol Brain (Bristol), Sr Susan Asterling, Sr
Deborah Kemp, Dr. Ben Hall (South Tyneside and Sunderland), and the
Urology Research team Freeman Hospital (Newcastle). We are also grateful
to all clinicians and nurse specialists in the trial sites for access to patients
and help in facilitating recruitment.
Authors’ contributions
VJG contributed to the study inception, design, data collation and analysis and
manuscript writing. LK contributed to the study analysis and manuscript writing.
PA, JA, SM and TB contributed to the data collation and manuscript writing.
KMB contributed to the sample analysis, data collation and manuscript writing.
AG contributed to the study co-ordination and data collation. NB contributed to
the manuscript writing. All authors read and approved the final manuscript.
Funding
This work was supported by an Addenbrookes Charitable Trust Innovation
Grant and an unrestricted education grant for reagents from Beckman
Coulter. Neither body had any influence or role in study design, execution,
analysis, manuscript drafting, or reporting. Infrastructure funding is
acknowledged from CRUK Cambridge Cancer Centre and the Cambridge
Biomedical Campus.
Availability of data and materials
All data is available by application to the study authors.
Ethics approval and consent to participate
The study was conducted under ethics REC 03/018. All participants
consented to anonymised blood samples and clinical data being used for
this study.
Competing interests
VJG has previously received a speaker honorarium from Beckman Coulter on
biomarkers in prostate cancer prior to the conception of this study. The
other authors declare that they have no competing interests.
Author details
1Department of Public Health and Primary Care, University of Cambridge,
Cambridge, UK. 2Department of Urology, Cambridge University Hospitals Trust,
Cambridge, UK. 3Urological Malignancies Programme CRUK & Cambridge
Urology Translational Research and Clinical Trials Office, University of Cambridge
Box 193, Cambridge Biomedical Campus Cambridge CB20QQ, Cambridge, UK.
4NIHR Cambridge Biomedical Research Centre, Core Biochemical Assay
Laboratory, University of Cambridge, Cambridge, UK. 5Department of Urology,
Southend Hospital, Essex, UK. 6Department of Urology, North Bristol NHS Trust,
Bristol, UK. 7Department of Urology, South Tyneside and Sunderland NHS Trust,
Sunderland, UK. 8Department of Urology, Newcastle Hospitals NHS Trust,
Newcastle upon Tyne, UK. 9Academic Urology Group, Department of Surgery,
University of Cambridge, Cambridge, UK.
Received: 14 December 2019 Accepted: 3 March 2020
References
1. Davies C, Castle JT, Stalbow K, Haslam PJ. Prostate mpMRI in the UK: the
state of the nation. Clin Radiol. 2019;74(11):894.e11–8. https://doi.org/10.
1016/j.crad.2019.09.129 Review.
2. Brizmohun Appayya M, Adshead J, Ahmed HU, Allen C, Bainbridge A,
Barrett T, Giganti F, Graham J, Haslam P, Johnston EW, Kastner C, Kirkham
APS, Lipton A, McNeill A, Moniz L, Moore CM, Nabi G, Padhani AR, Parker C,
Patel A, Pursey J, Richenberg J, Staffurth J, van der Meulen J, Walls D,
Punwani S. National implementation of multi-parametric magnetic
resonance imaging for prostate cancer detection - recommendations from
a UK consensus meeting. BJU Int. 2018;122(1):13–25.
3. Rouviere O, Moldovan PC. The current role of prostate multiparametric
magnetic resonance imaging. Asian J Urol. 2019;6(2):137–45.
4. https://uroweb.org/guideline/prostate-cancer/. Accessed 11 11 2019.
5. Dasgupta P, Davis J, Hughes S. NICE guidelines on prostate cancer 2019.
BJU Int. 2019;124(1):1.
6. Smith-Palmer J, Takizawa C, Valentine W. Literature review of the burden of
prostate cancer in Germany, France, the United Kingdom and Canada. BMC
Urol. 2019;19(1):19.
7. Rawla P. Epidemiology of prostate cancer. World J Oncol. 2019;10(2):63–89.
https://doi.org/10.14740/wjon1191.
8. Rider JR, Sandin F, Andrén O, Wiklund P, Hugosson J, Stattin P. Long-term
outcomes among noncuratively treated men according to prostate cancer
risk category in a nationwide, population-based study. Eur Urol. 2013;63(1):
88–96.
9. Kohestani K, Wallström J, Dehlfors N, Sponga OM, Månsson M, Josefsson A,
Carlsson S, Hellström M, Hugosson J. Performance and inter-observer
variability of prostate MRI (PI-RADS version 2) outside high-volume centres.
Scand J Urol. 2019;29:1–8.
10. Pickersgill NA, Vetter JM, Andriole GL, Shetty AS, Fowler KJ, Mintz AJ, Siegel CL,
Kim EH. Accuracy and variability of prostate multiparametric magnetic resonance
imaging interpretation using the prostate imaging reporting and data system: a
blinded comparison of radiologists. Eur Urol Focus. 2020;6(2):267–72.
11. Moldovan PC, Van den Broeck T, Sylvester R, Marconi L, Bellmunt J, van
denBergh RCN, Bolla M, Briers E, Cumberbatch MG, Fossati N, Gross T, Henry
AM, Joniau S, van der Kwast TH, Matveev VB, van der Poel HG, De Santis M,
Schoots IG, Wiegel T, Yuan CY, Cornford P, Mottet N, Lam TB, Rouvière O.
What is the negative predictive value of multiparametric magnetic
resonance imaging in excluding prostate cancer at biopsy? A systematic
review and meta-analysis from the European Association of Urology
Prostate Cancer Guidelines Panel. Eur Urol. 2017;72(2):250–66.
12. Busetto GM, De Berardinis E, Sciarra A, Panebianco V, Giovannone R, Rosato S,
D'Errigo P, Di Silverio F, Gentile V, Salciccia S. Prostate cancer gene 3 and
multiparametric magnetic resonance can reduce unnecessary biopsies: decision
curve analysis to evaluate predictive models. Urology. 2013;82(6):1355–60.
13. Marzouk K, Ehdaie B, Vertosick E, Zappala S, Vickers A. Developing an effective
strategy to improve the detection of significant prostate cancer by combining
the 4Kscore and multiparametric MRI. Urol Oncol. 2019;37(10):672–7.
14. Grönberg H, Eklund M, Picker W, Aly M, Jäderling F, Adolfsson J, Landquist
M, Haug ES, Ström P, Carlsson S, Nordström T. Prostate cancer diagnostics
using a combination of the Stockholm3 blood test and multiparametric
magnetic resonance imaging. Eur Urol. 2018;74(6):722–8.
15. Hendriks RJ, van der Leest MMG, Dijkstra S, Barentsz JO, Van Criekinge W,
Hulsbergen-van de Kaa CA, Schalken JA, Mulders PFA, van Oort IM. A
urinary biomarker-based risk score correlates with multiparametric MRI for
prostate cancer detection. Prostate. 2017;77(14):1401–7.
16. Schoots IG, Padhani AR. Personalizing prostate cancer diagnosis with
multivariate risk prediction tools: how should prostate MRI be incorporated?
World J Urol. 2019. https://doi.org/10.1007/s00345-019-02899-0.
17. Kohaar I, Petrovics G, Srivastava S. A rich array of prostate cancer molecular
biomarkers: opportunities and challenges. Int J Mol Sci. 2019;20(8):1813.
https://doi.org/10.3390/ijms20081813.
18. Lamy PJ, Allory Y, Gauchez AS, Asselain B, Beuzeboc P, de Cremoux P,
Fontugne J, Georges A, Hennequin C, Lehmann-Che J, Massard C, Millet I,
Murez T, Schlageter MH, Rouvière O, Kassab-Chahmi D, Rozet F, Descotes JL,
Rébillard X. Prognostic biomarkers used for localised prostate cancer
management: a systematic review. Eur Urol Focus. 2018;4(6):790–803.
Kim et al. BMC Medicine           (2020) 18:95 Page 8 of 9
19. Mathieu R, Castelli C, Fardoun T, Peyronnet B, Shariat SF, Bensalah K,
Vincendeau S. Cost analysis of prostate cancer detection including the
prostate health index (phi). World J Urol. 2019;37(3):481–7.
20. Wang W, Wang M, Wang L, Adams TS, Tian Y, Xu J. Diagnostic ability of
%p2PSA and prostate health index for aggressive prostate cancer: a meta-
analysis. Sci Rep. 2014;4:5012. https://doi.org/10.1038/srep05012.
21. Gnanapragasam VJ, Burling K, George A, Stearn S, Warren A, Barrett T, Koo B,
Gallagher FA, Doble A, Kastner C, Parker RA. The prostate health index adds
predictive value to multi-parametric MRI in detecting significant prostate
cancers in a repeat biopsy population. Sci Rep. 2016;6:35364.
22. Gnanapragasam VJ, Bratt O, Muir K, Lee LS, Huang HH, Stattin P,
Lophatananon A. The Cambridge Prognostic Groups for improved
prediction of disease mortality at diagnosis in primary non-metastatic
prostate cancer: a validation study. BMC Med. 2018;16(1):31.
23. Zelic R, Garmo H, Zugna D, Stattin P, Richiardi L, Akre O, Pettersson A.
Predicting prostate cancer death with different pretreatment risk stratification
tools: a head-to-head comparison in a nationwide cohort study. Eur Urol. 2019.
24. http://www.auanet.org/guidelines/clinically-localized-prostate-cancer-new-
aua/astro/suo-guideline-2017. Accessed 12 11 19.
25. Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating
prediction models. Med Decis Mak. 2006;26(6):565–74.
26. Batura D, Gopal RG. The national burden of infections after prostate biopsy
in England and Wales: a wake-up call for better prevention--authors'
response. J Antimicrob Chemother. 2013;68(10):2419–20.
27. Hex N, Retzler J, Bartlett C, Arber M. The cost of sepsis care in the UK: York
Health Economics Consortium; 2017. http://allcatsrgrey.org.uk/wp/wpfb-file/
yhec-sepsis-report-17-02-17-final-pdf. Last accessed 13 Dec 2018.
28. Porpiglia F, Russo F, Manfredi M, Mele F, Fiori C, Bollito E, Papotti M, Molineris I,
Passera R, Regge D. The roles of multiparametric magnetic resonance imaging,
PCA3 and prostate health index-which is the best predictor of prostate cancer
after a negative biopsy? J Urol. 2014;192(1):60–6.
29. Sciarra A, Panebianco V, Cattarino S, Busetto GM, De Berardinis E, Ciccariello
M, Gentile V, Salciccia S. Multiparametric magnetic resonance imaging of
the prostate can improve the predictive value of the urinary prostate cancer
antigen 3 test in patients with elevated prostate-specific antigen levels and
a previous negative biopsy. BJU Int. 2012;110(11):1661–5.
30. Osses DF, Roobol MJ, Schoots IG. Prediction medicine: biomarkers, risk
calculators and magnetic resonance imaging as risk stratification tools in
prostate cancer diagnosis. Int J Mol Sci. 2019;20(7):E1637.
31. Ling DI, Lynd LD, Harrison M, Anis AH, Bansback N. Early cost-effectiveness
modeling for better decisions in public research investment of personalized
medicine technologies. J Comp Eff Res. 2019;8(1):7–19.
32. Verbeek JFM, Bangma CH, Kweldam CF, van der Kwast TH, Kümmerlin IP, van
Leenders GJLH, Roobol MJ. Reducing unnecessary biopsies while detecting
clinically significant prostate cancer including cribriform growth with the
ERSPC Rotterdam risk calculator and 4Kscore. Urol Oncol. 2019;37(2):138–44.
33. Loeb S, Shin SS, Broyles DL, Wei JT, Sanda M, Klee G, Partin AW, Sokoll L,
Chan DW, Bangma CH, van Schaik RHN, Slawin KM, Marks LS, Catalona WJ.
Prostate Health Index improves multivariable risk prediction of aggressive
prostate cancer. BJU Int. 2017;120(1):61–8.
34. Mannaerts CK, Gayet M, Verbeek JF, Engelbrecht MRW, Savci-Heijink CD,
Jager GJ, Gielens MPM, van der Linden H, Beerlage HP, de Reijke TM,
Wijkstra H, Roobol MJ. Prostate cancer risk assessment in biopsy-naïve
patients: the Rotterdam prostate cancer risk calculator in multiparametric
magnetic resonance imaging-transrectal ultrasound (TRUS) fusion biopsy
and systematic TRUS biopsy. Eur Urol Oncol. 2018;1(2):109–17.
35. Alberts AR, Roobol MJ, Verbeek JFM, Schoots IG, Chiu PK, Osses DF,
Tijsterman JD, Beerlage HP, Mannaerts CK, Schimmöller L, Albers P, Arsov C.
Prediction of high-grade prostate cancer following multiparametric
magnetic resonance imaging: improving the Rotterdam European
randomized study of screening for prostate cancer risk calculators. Eur Urol.
2019;75(2):310–8.
36. Kang Z, Min X, Weinreb J, Li Q, Feng Z, Wang L. Abbreviated biparametric versus
standard multiparametric MRI for diagnosis of prostate cancer: a systematic
review and meta-analysis. AJR Am J Roentgenol. 2019;212(2):357–65.
37. Walz J. Let’s keep it at one step at a time: why biparametric magnetic
resonance imaging is not the priority today. Eur Urol. 2019;76(5):582–3.
38. Heijnsdijk EA, Denham D, de Koning HJ. The cost-effectiveness of prostate
cancer detection with the use of prostate health index. Value Health. 2016;
19(2):153–7.
39. Nichol MB, Wu J, Huang J, Denham D, Frencher SK, Jacobsen SJ. Cost-
effectiveness of prostate health index for prostate cancer detection. BJU Int.
2012;110(3):353–62.
40. Sathianathen NJ, Kuntz KM, Alarid-Escudero F, Lawrentschuk NL, Bolton DM,
Murphy DG, Weight CJ, Konety BR. Incorporating biomarkers into the
primary prostate biopsy setting: a cost-effectiveness analysis. J Urol. 2018;
200(6):1215–20.
41. Rouvière O, Puech P, Renard-Penna R, Claudon M, Roy C, Mège-Lechevallier F,
Decaussin-Petrucci M, Dubreuil-Chambardel M, Magaud L, Remontet L, Ruffion A,
Colombel M, Crouzet S, Schott AM, Lemaitre L, Rabilloud M, Grenier N, MRI-FIRST
Investigators. Use of prostate systematic and targeted biopsy on the basis of
multiparametric MRI in biopsy-naive patients (MRI-FIRST): a prospective,
multicentre, paired diagnostic study. Lancet Oncol. 2019;20(1):100–9.
42. van der Leest M, Cornel E, Israël B, Hendriks R, Padhani AR, Hoogenboom M,
Zamecnik P, Bakker D, Setiasti AY, Veltman J, van den Hout H, van der Lelij
H, van Oort I, Klaver S, Debruyne F, Sedelaar M, Hannink G, Rovers M,
Hulsbergen-van de Kaa C, Barentsz JO. Head-to-head comparison of
transrectal ultrasound-guided prostate biopsy versus multiparametric
prostate resonance imaging with subsequent magnetic resonance-guided
biopsy in biopsy-naïve men with elevated prostate-specific antigen: a large
prospective multicenter clinical study. Eur Urol. 2019;75(4):570–8.
43. Monda SM, Vetter JM, Andriole GL, Fowler KJ, Shetty AS, Weese JR, Kim EH.
Cognitive versus software fusion for MRI-targeted biopsy: experience before
and after implementation of fusion. Urology. 2018;119:115–20.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Kim et al. BMC Medicine           (2020) 18:95 Page 9 of 9
